Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,758 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
Interventions: Behavioral Activation, Medication Optimization, Usual care resources; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Schizophrenia, Bipolar Disorder, Depression
Interventions: Individual placement and support plus cognitive training (IPS-CT), Individual placement and support plus enhanced support (IPS-ES); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Major Depressive Disorder, MDD, Depression, Major Depressive Episode
Interventions: transcranial direct current stimulation (tDCS); Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 46
States / cities: Tucson, Arizona • Anaheim, California • Culver City, California + 37 more

Conditions: Major Depressive Disorder
Interventions: ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents; Drug · Other · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depression
Interventions: Guideline-Based Medical Management, Motivational Interviewing for Depression; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Major Depressive Disorder, Dysthymia
Interventions: Stepped Care IPT-A (SCIPT-A), Treatment as Usual; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 13 Years to 20 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder, Borderline Personality Disorder, Generalized Anxiety Disorder
Interventions: Survey; Other
Lead sponsor: Adams Clinical; Network
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Watertown, Massachusetts • New York, New York + 3 more

Conditions: Major Depressive Disorder
Interventions: Active transcutaneous spinal direct current stimulation, Sham transcutaneous spinal direct current stimulation; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Major Depressive Disorder
Interventions: NEST-1 (NeoSync EEG Synchronized TMS), SHAM; Device
Lead sponsor: Wave Neuroscience; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 15 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more

Conditions: Depression
Interventions: desvenlafaxine SR, desipramine, paroxetine; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Depressive Disorder, Major, Suicidal Ideation
Interventions: Ketamine; Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Depressive Disorder
Interventions: Saredutant succinate (SR48968C); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
Interventions: Medi-TBS; Combination Product
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Major Depressive Disorder
Interventions: Sertraline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 60 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Depressive Disorder, Major, Suicide
Interventions: Accelerated Theta Burst Stimulation, Sham Stimulation; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Major Depressive Disorder
Interventions: desvenlafaxine succinate sustained-release, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 44
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 38 more

Conditions: Major Depression
Interventions: L-leucine, L-lysine; Drug
Lead sponsor: Emory University; Other
Eligibility: 35 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions: MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation; Device · Other
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 25 Years to 64 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: SP-624, Placebo; Drug
Lead sponsor: Sirtsei Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 46 more

Conditions: Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
Interventions: Smartphone App, Waitlist Control; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depression, Depression Moderate, Depression Severe, Depression Mild
Interventions: Kintsugi Voice Device; Device
Lead sponsor: Kintsugi Mindful Wellness, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Berkeley, California

Search by objective public record fields.

Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery

Cognitive Training to Improve Work Outcomes in Severe Mental Illness

tDCS: Sleep to Mood in Depression (S2M-D)

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

Motivational Interviews for Depression in Primary Care

A Stepped Care Model of Adolescent Depression Treatment in Primary Care

Triage Survey for Psychiatry Research Eligibility

Spinal Cord Stimulation for the Treatment of Major Depressive Disorder

Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

Ketamine for Mood Disorders With Suicidal Ideation

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

Mindfulness Engaged Neurostimulation for Depression

Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression

Rapid Acting TMS for Suicide Ideation in Depression

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Leucine in Midlife Depression

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Evaluation of mHealth for Serious Mental Illness

Kintsugi Voice Device Pivotal Study